Clinical Trials Logo

Advanced Malignant Solid Tumors clinical trials

View clinical trials related to Advanced Malignant Solid Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06231550 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard anti-cancer treatment.

NCT ID: NCT05886374 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Start date: July 6, 2023
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-415S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor.

NCT ID: NCT05773937 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Start date: June 21, 2022
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.

NCT ID: NCT05749627 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the neoantigen-based DC treatment.

NCT ID: NCT05338957 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Start date: August 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to assess the safety and tolerability of MRG002 in combination with HX008 in patients with HER2-expressed advanced malignant solid tumors; and to , explore the maximum tolerated dose (MTD), and to determine the recommended phase II dose (RP2D) of combination therapy; , and to evaluate the preliminary efficacy, pharmacokinetics, and immunogenicity of combination therapy in the targeted study population.

NCT ID: NCT05277454 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT

Start date: January 18, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose (MTD) and/or the recommended phase II clinical study dose (RP2D) of HMPL-653 in patients with advanced solid tumors.

NCT ID: NCT04908046 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Start date: May 27, 2021
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor. It will be extended to enroll 10-15 patients at this dose after RP2D is determined, as to further evaluate the safety of RP2D and the preliminary efficacy of HMPL-295S1. In addition, an exploratory study on the pharmacokinetic biomarkers of HMPL-295S1 is planned in this study.

NCT ID: NCT04226066 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Start date: November 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This open, dose-escalation and extended PhI/IIa clinical trial aims to evaluate the safety, tolerability of T601 as a single-agent as well as combined with prodrug 5-FC to treat patients with advanced malignant solid tumors and to explore the pharmacokinetic characteristics of T601, 5-FC, 5-FU, FBAL, which includes PhI study of dose-escalation study and Ph IIa study of extending study.

NCT ID: NCT03047811 Recruiting - Clinical trials for Advanced Malignant Solid Tumors

The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors

Start date: August 26, 2016
Phase: N/A
Study type: Interventional

The study of targeted NY-ESO-1 T cell receptor (TCR) genetic modified autologous T cells treatment of advanced solid tumors 1. The main purpose - security and ORR; 2. A secondary purpose - median progression-free surial;1 year, 2 years, total 5 years survival rate;The quality of life.